Get started
Author

Anette Ligl-Löhner

OpenAlex ID: A5003474647
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al. · Clinical Cancer Research · 2
Expression VIII: Final Results of the Individual Perception and Level of Information of Patients with Borderline Tumors of the Ovary
2026 · Sara Alavi-Demirci, Laura N. Beckmann, et al. · Current Oncology
EXPRESSION VIII: final results of the individual perception and level of information of patients with borderline tumor of the ovary
2026 · Sara Alavi-Demirci, Hannah Woopen, et al. · International Journal of Gynecological Cancer
Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S6 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
Supplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S3 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S7 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
2022-RA-576-ESGO Expression VIII – first study of individual perception and level of information of patients with low grade ovarian cancer and borderline tumor of the ovary in 321 patients
2022 · Laura Naomi Beckmann, Sara Alavi, et al. · International Journal of Gynecological Cancer
PDF
Works count: 13
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type